Novartis has struck a front-loaded deal to buy Synnovation Therapeutics’ pan-mutant‑selective PI3Kα inhibitor for $2 billion, ...

Gilead has handed back a next-gen hepatitis B antiviral to Assembly Biosciences, while the two companies continue to partner ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Genentech is halting development of an antibody for two rare genetic diseases after the candidate failed to boost muscle growth, raising questions about whether the molecule can preserve muscle in two ...

About a month after Pfizer CEO Albert Bourla, Ph.D., told investors that the Big Pharma’s pipeline pruning was mostly done, ...

As Eli Lilly begins to take the next generation of obesity drugs to regulators this year, a lower-profile collaboration ...

Since Xaira’s eye-popping $1 billion fundraise in 2024, the company has said relatively little in public. | What has Xaira been doing since its $1 billion raise? Xaira COO Jeff Jonker joins "The Top ...

Swiss pharma Roche is staying in lockstep with Eli Lilly, expanding its artificial intelligence offerings and Nvidia ...

R1 Therapeutics is debuting with an oversubscribed $77.5 million series A financing aimed at advancing its first-in-class ...

Stoke Therapeutics is developing a drug designed to reduce seizures and restore some of their lost developmental function.

Genentech has elected to stop a phase 2 trial of a RIPK1 inhibitor early and dump the asset after an analysis revealed the candidate was unlikely to meet the study’s primary endpoint. | Genentech has ...

With the obesity numbers for Eli Lilly’s retatrutide already stacking up nicely, the company has rounded out its pitch for the triple agonist with top-line data on its ability to lower blood sugar ...